Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

BACKGROUND: We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: VISNÚ-2 was a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESMO Open
Autors principals: Sastre, J., García-Alfonso, P., Viéitez, J.M., Cano, M.T., Rivera, F., Reina-Zoilo, J.J., Salud-Salvia, A., Quintero, G., Robles-Díaz, L., Safont, M.J., La Casta, A., Gil, S., Polo, E., Asensio-Martínez, E., García-Paredes, B., López, R.L., Guillot, M., Valladares-Ayerbes, M., Aranda, E., Díaz-Rubio, E.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970062/
https://ncbi.nlm.nih.gov/pubmed/33711671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100062
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars